The earnings call reflects a strong positive sentiment with significant advancements in clinical data and strategic financial moves. The highlights, particularly in clinical trial progress and promising data across several cancer types, outweigh the challenges such as the ongoing CEO search and reduced R&D spending.

Company Guidance

During the first quarter conference call for Oncolytics Biotech in 2025, the company provided guidance on several key metrics related to the development of their cancer therapeutic, pelareorep (pela). They reported cash and cash equivalents of $15.3 million, which is expected to provide financial runway through the third quarter of 2025. Net cash used in operating activities was $6.5 million, a decrease from $7.5 million in the same period last year. General and administrative expenses remained consistent at $3 million, while research and development expenses decreased to $4.1 million from $5.7 million in Q1 2024. The net loss for the quarter was $6.7 million, or $0.08 per share, compared to $6.9 million or $0.09 per share in the previous year. The company also announced a $20 million share purchase agreement with Alumni Capital to extend their financial runway. Oncolytics is advancing their clinical trials, particularly focusing on breast and pancreatic cancer, with promising efficacy data from randomized Phase 2 studies and plans for future registrational opportunities.

Clinical Data Exceeds Expectations

Oncolytics Biotech's clinical data for pelareorep continues to exceed expectations, particularly in difficult-to-treat malignancies such as pancreatic cancer, breast cancer, and anal carcinoma.

Positive Results in Breast Cancer Studies

Pelareorep-based combination therapy substantially outperformed standard care treatments in two randomized Phase 2 studies for HR-positive/HER2-negative metastatic breast cancer.

Promising Pancreatic and Anal Cancer Data

Interim results from the GOBLET Cohort 4 showed a 33% objective response rate in relapsed anal carcinoma, including a complete response lasting over 15 months. Additionally, the pancreatic cancer cohort is progressing with more than half of the required patients enrolled.

Favorable Safety Profile and Versatility

Pelareorep demonstrates a remarkable safety profile and versatility, showing potential in multiple cancer types and combinations with different chemotherapies and checkpoint inhibitors.

Financial Flexibility Through Share Purchase Agreement

A $20 million share purchase agreement with Alumni Capital provides Oncolytics with access to capital, enhancing financial flexibility.

Oncolytics Biotech (ONCY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ONCY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.06 / -	-0.087	―	―	―
Aug 08, 2025	2025 (Q2)	-0.07 / -0.05	-0.073	30.00% (+0.02)	―	―
May 14, 2025	2025 (Q1)	-0.07 / -0.06	-0.065	11.11% (<+0.01)	―
Mar 07, 2025	2024 (Q4)	-0.09 / -0.07	-0.036	-100.00% (-0.04)	―
Nov 12, 2024	2024 (Q3)	-0.07 / -0.09	-0.102	14.29% (+0.01)	―
Aug 01, 2024	2024 (Q2)	-0.07 / -0.07	-0.087	16.67% (+0.01)	―
May 09, 2024	2024 (Q1)	-0.08 / -0.07	-0.073	10.00% (<+0.01)	―
Mar 07, 2024	2023 (Q4)	-0.11 / -0.04	-0.102	64.29% (+0.07)	―
Nov 03, 2023	2023 (Q3)	-0.08 / -0.10	-0.058	-75.00% (-0.04)	―
Aug 14, 2023	2023 (Q2)	-0.09 / -0.09	-0.065	-33.33% (-0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ONCY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 08, 2025	$0.92	$0.86	-6.52%
May 14, 2025	$0.52	$0.50	-3.85%
Mar 07, 2025	$0.74	$0.69	-6.76%
Nov 12, 2024	$1.08	$1.12	+3.70%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Oncolytics Biotech (ONCY) report earnings?

Oncolytics Biotech (ONCY) is schdueled to report earning on Nov 12, 2025, TBA (Confirmed).

What is Oncolytics Biotech (ONCY) earnings time?

Oncolytics Biotech (ONCY) earnings time is at Nov 12, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ONCY EPS forecast?

ONCY EPS forecast for the fiscal quarter 2025 (Q3) is -0.06.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing